Harte Hanks Gelecekteki Büyüme
Future kriter kontrolleri 0/6
Harte Hanks is forecast to grow earnings and revenue by 124.9% and 3.1% per annum respectively while EPS is expected to grow by 125% per annum.
Anahtar bilgiler
124.9%
Kazanç büyüme oranı
125.0%
EPS büyüme oranı
Media kazanç büyümesi | 13.1% |
Gelir büyüme oranı | 3.1% |
Gelecekteki özkaynak getirisi | n/a |
Analist kapsamı | Low |
Son güncelleme | 14 Aug 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Investors Aren't Entirely Convinced By Harte Hanks, Inc.'s (NASDAQ:HHS) Revenues
Jul 03With EPS Growth And More, Harte Hanks (NASDAQ:HHS) Makes An Interesting Case
Nov 03Harte Hanks, Inc.'s (NASDAQ:HHS) Intrinsic Value Is Potentially 30% Above Its Share Price
Oct 13Harte Hanks (NASDAQ:HHS) Is Experiencing Growth In Returns On Capital
Jun 08Should You Investigate Harte Hanks, Inc. (NASDAQ:HHS) At US$8.83?
Mar 16Does Harte Hanks (NASDAQ:HHS) Deserve A Spot On Your Watchlist?
Feb 22Are Investors Undervaluing Harte Hanks, Inc. (NASDAQ:HHS) By 22%?
Dec 07If EPS Growth Is Important To You, Harte Hanks (NASDAQ:HHS) Presents An Opportunity
Oct 27Harte Hanks: Good Point To Start Accumulation Again (Technical Analysis)
Sep 27Harte Hanks (NASDAQ:HHS) Could Become A Multi-Bagger
Sep 19Harte Hanks and FEVO announce expanding partnership
Sep 15Harte Hanks: Mean Reversion Imminent, But Still A Buy For Patient Investors
Aug 23Harte Hanks, Inc. (NASDAQ:HHS) Stock Catapults 25% Though Its Price And Business Still Lag The Market
Aug 13Harte Hanks GAAP EPS of $0.52 beats by $0.24, revenue of $48.6M misses by $0.7M
Aug 11What Does Harte Hanks, Inc.'s (NASDAQ:HHS) Share Price Indicate?
Jul 26Harte Hanks: This Top-Rated Micro-Cap Stock Has A Great Growth Potential
Jul 14Harte-Hanks: Deep Valuation And Future Growth Could Double The Stock
May 23Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
12/31/2025 | 195 | 9 | 9 | 13 | 1 |
12/31/2024 | 188 | -26 | -25 | -22 | 1 |
6/30/2024 | 187 | -29 | -1 | 2 | N/A |
3/31/2024 | 190 | -1 | 0 | 3 | N/A |
12/31/2023 | 191 | -2 | 8 | 10 | N/A |
9/30/2023 | 197 | 23 | 11 | 13 | N/A |
6/30/2023 | 204 | 29 | 20 | 24 | N/A |
3/31/2023 | 204 | 32 | 26 | 31 | N/A |
12/31/2022 | 206 | 35 | 23 | 29 | N/A |
9/30/2022 | 203 | 14 | 20 | 26 | N/A |
6/30/2022 | 199 | 12 | 7 | 13 | N/A |
3/31/2022 | 200 | 17 | -1 | 3 | N/A |
12/31/2021 | 195 | 13 | -5 | -2 | N/A |
9/30/2021 | 190 | 12 | -6 | -2 | N/A |
6/30/2021 | 188 | 7 | -9 | -5 | N/A |
3/31/2021 | 180 | -8 | -12 | -10 | N/A |
12/31/2020 | 177 | -2 | -11 | -8 | N/A |
9/30/2020 | 182 | -6 | -11 | -9 | N/A |
6/30/2020 | 186 | -11 | -12 | -11 | N/A |
3/31/2020 | 199 | -9 | 8 | 11 | N/A |
12/31/2019 | 218 | -27 | 9 | 12 | N/A |
9/30/2019 | 235 | -22 | 4 | 7 | N/A |
6/30/2019 | 248 | -26 | 0 | 4 | N/A |
3/31/2019 | 263 | -28 | -19 | -15 | N/A |
12/31/2018 | 285 | 15 | -13 | -9 | N/A |
9/30/2018 | 314 | -16 | 0 | 4 | N/A |
6/30/2018 | 345 | -8 | 9 | 14 | N/A |
3/31/2018 | 370 | -5 | N/A | -27 | N/A |
12/31/2017 | 384 | -42 | N/A | -31 | N/A |
9/30/2017 | 394 | -85 | N/A | -54 | N/A |
6/30/2017 | 397 | -86 | N/A | -49 | N/A |
3/31/2017 | 400 | -90 | N/A | 9 | N/A |
12/31/2016 | 404 | -90 | N/A | 15 | N/A |
9/30/2016 | 411 | -18 | N/A | 32 | N/A |
6/30/2016 | 423 | -188 | N/A | 28 | N/A |
3/31/2016 | 434 | -187 | N/A | 18 | N/A |
12/31/2015 | 444 | -181 | N/A | 33 | N/A |
9/30/2015 | 474 | -170 | N/A | 36 | N/A |
6/30/2015 | 499 | 9 | N/A | 41 | N/A |
3/31/2015 | 530 | 22 | N/A | 39 | N/A |
12/31/2014 | 499 | 14 | N/A | 26 | N/A |
9/30/2014 | 559 | 21 | N/A | 43 | N/A |
6/30/2014 | 560 | 19 | N/A | 41 | N/A |
3/31/2014 | 560 | 20 | N/A | 54 | N/A |
12/31/2013 | 560 | 24 | N/A | 60 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: HHS is forecast to remain unprofitable over the next 3 years.
Kazançlar ve Piyasa: HHS is forecast to remain unprofitable over the next 3 years.
Yüksek Büyüme Kazançları: HHS is forecast to remain unprofitable over the next 3 years.
Gelir ve Pazar: HHS's revenue (3.1% per year) is forecast to grow slower than the US market (8.9% per year).
Yüksek Büyüme Geliri: HHS's revenue (3.1% per year) is forecast to grow slower than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: Insufficient data to determine if HHS's Return on Equity is forecast to be high in 3 years time